Treatment of T-ALL, PTCL, and CD7-positive AML patient-derived blood samples in vitro. (A) Blood cells derived from 4 patients with T-ALL, 1 patient with PTCL, and 1 patient with CD7-positive AML were subjected to treatment with scFvCD7:sFasL (150 ng/mL) and analyzed for apoptosis induction using annexin V/PI staining. (B) Primary CD7-positive AML cells were subjected to treatment with scFvCD7:sFasL alone or in the presence of mAb TH69 for 16 hours, after which apoptosis was assessed by annexin V/PI staining. Statistical analysis was performed using 2-tailed Student t test. ^*P < .05. (C) Primary T-ALL cells were subjected to scFvCD7:sFasL (150 ng/mL) and then assessed for the presence of active caspase-3 using fluorescent microscopy as described in “Fluorescence microscopy of activated caspase-3.” (D) Primary CD7-positive AML cells were subjected to single-agent treatment with scFvCD7:sFasL (100 ng/mL), vincristine (10 ng/mL), amsacrine (1 μM), or to combination treatment. Apoptosis was assessed by annexin V/PI staining. The CI was used to determine the cooperative effect of combination treatment.